Community Advisory Board

Readers Rep

Markets:

Overview

News

Currencies

International

Treasuries

Aligos Therapeutics, Inc. - Common stock (NQ:ALGS)

8.172 +0.053 (+0.65%)

Streaming Delayed Price Updated: 11:00 AM EST, Jan 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aligos Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 Next >

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results

November 02, 2022

From Aligos Therapeutics

Via GlobeNewswire

Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022

October 21, 2022

From Aligos Therapeutics

Via GlobeNewswire

Aligos Therapeutics to Announce Third Quarter Results November 2, 2022

October 19, 2022

From Aligos Therapeutics

Via GlobeNewswire

Aligos Co-Founders File Complaint Against Johnson & Johnson Alleging Fraud ↗

September 29, 2022

Via Benzinga

Where Aligos Therapeutics Stands With Analysts ↗

May 05, 2022

Within the last quarter, Aligos Therapeutics (NASDAQ:ALGS) has observed the following analyst ratings:

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

April 08, 2022

During Friday's morning session, 234 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap...

Via Benzinga

Aligos Pulls Plug On Early-Stage Chronic Hepatitis B Treatment Candidate ↗

March 22, 2022

Aligos Therapeutics Inc (NASDAQ: ALGS) has

Via Benzinga

Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA

October 18, 2022

Aligos’ pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023

From Aligos Therapeutics

Via GlobeNewswire

Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755

October 14, 2022

From Aligos Therapeutics

Via GlobeNewswire

Aligos Therapeutics Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud

September 28, 2022

From Aligos Therapeutics

Via GlobeNewswire

Earnings Scheduled For March 10, 2022 ↗

March 10, 2022

Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares...

Via Benzinga

Aligos Therapeutics's Return On Capital Employed Overview ↗

August 23, 2022

According to Benzinga Pro data, during Q2, Aligos Therapeutics (NASDAQ:ALGS) posted sales of $3.69 million. Earnings were up 44.06%, but Aligos Therapeutics still reported an overall loss of $19.92...

Via Benzinga

Aligos Therapeutics Earnings Preview ↗

August 03, 2022

Aligos Therapeutics (NASDAQ:ALGS) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's what investors need to know before the announcement. Analysts estimate that Aligos...

Via Benzinga

Aligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022

July 27, 2022

From Aligos Therapeutics

Via GlobeNewswire

Aligos Shares Fall Following Commencement Of Initial-Stage Chronic Hepatitis B Study ↗

July 25, 2022

Aligos Therapeutics, Inc. (NASDAQ: ALGS) has initiated enrollment in a 12-week dosing cohort of HBeAg-positive chronic hepatitis B (CHB) subjects in the ongoing Phase 1b study ALG-000184-201.

Via Benzinga

Aligos Therapeutics's Return On Capital Employed Insights ↗

May 23, 2022

According to Benzinga Pro data, during Q1, Aligos Therapeutics (NASDAQ:ALGS) posted sales of $2.57 million. Earnings were up 5.57%, but Aligos Therapeutics still reported an overall loss of $35.62...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022 ↗

May 05, 2022

Upgrades

Via Benzinga

Preview: Aligos Therapeutics's Earnings ↗

May 03, 2022

Aligos Therapeutics (NASDAQ:ALGS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Aligos...

Via Benzinga

NASDAQ: ALGS Investor Notice: Investigation over Potential Wrongdoing at Aligos Therapeutics, Inc. ↗

April 15, 2022

San Diego, CA -- (SBWIRE) -- 04/15/2022 -- An investigation on behalf of investors in Aligos Therapeutics, Inc. (NASDAQ: ALGS) shares over potential wrongdoing at Aligos Therapeutics, Inc. was...

Via SBWire

Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2022 ↗

March 23, 2022

Upgrades For E2open Parent Holdings Inc (NYSE:ETWO), Colliers Securities upgraded the previous rating of Neutral to Buy. At the moment, the stock has a 52-week-high of $14.58 and...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

March 31, 2022

On Thursday, 92 companies hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week...

Via Benzinga

63 Biggest Movers From Yesterday ↗

March 25, 2022

Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares gained 39.1% to close at $1.05 on Thursday. The company recently said its CFO Bruce Colwill will retire. Global Internet...

Via Benzinga

10 Biggest Price Target Changes For Wednesday ↗

March 23, 2022

SVB Leerink cut the price target on TCR2 Therapeutics Inc. (NASDAQ: TCRR) from $7 to $3. TCR2 Therapeutics shares rose 16% to close at $3.19 on Tuesday.

Via Benzinga

Recap: Aligos Therapeutics Q4 Earnings ↗

March 10, 2022

Aligos Therapeutics (NASDAQ:ALGS) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Aligos Therapeutics Earnings Preview ↗

March 09, 2022

Aligos Therapeutics (NASDAQ:ALGS) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

10 Biggest Price Target Changes For Wednesday ↗

February 16, 2022

Needham raised Airbnb, Inc. (NASDAQ: ABNB) price target from $210 to $220. Airbnb shares rose 3.1% to $185.70 in pre-market trading.

Via Benzinga

Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes ↗

February 11, 2022

Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels.

Via Investor's Business Daily

SHAREHOLDER ALERT: Robbins LLP Investigates Aligos Therapeutics, Inc. (ALGS) on Behalf of Shareholders

January 28, 2022

From Robbins LLP

Via Business Wire

Stocks That Hit 52-Week Lows On Thursday ↗

February 17, 2022

On Thursday, 147 companies achieved new lows for the year. Significant Points From Today's 52-Week Lows: PayPal Holdings (NASDAQ:PYPL) was the biggest company...

Via Benzinga

NASDAQ: ALGS Shareholder Notice: Investigation over Potential Securities Laws Violations by Aligos Therapeutics, Inc. ↗

January 24, 2022

San Diego, CA -- (SBWIRE) -- 01/24/2022 -- An investigation for investors in Aligos Therapeutics, Inc. (NASDAQ: ALGS) shares over potential securities laws violations by Aligos Therapeutics, Inc. was...

Via SBWire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

About Us

Aligos Therapeutics, Inc. - Common stock (NQ:ALGS)

All News about Aligos Therapeutics, Inc. - Common stock